# In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

> **NCT00631072** · PHASE1 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 9 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** INKT
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT00631072
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2014-08
- **Final completion:** 2015-04
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00631072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00631072, "In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00631072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*